WuXi XDC Cayman Inc
Company Profile
Business description
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.
Contact
No. 11 Xinhui Ring Road
Xinwu
Jiangsu
Wuxi
CHNSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
1,496
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,524.30 | 323.30 | -4.12% |
| CAC 40 | 6,850.94 | 424.01 | -5.83% |
| DAX 40 | 19,409.65 | 1,232.07 | -5.97% |
| Dow JONES (US) | 38,314.86 | 2,231.07 | -5.50% |
| FTSE 100 | 7,654.59 | 400.39 | -4.97% |
| HKSE | 19,710.26 | 3,139.55 | -13.74% |
| NASDAQ | 15,587.79 | 962.82 | -5.82% |
| Nikkei 225 | 31,136.58 | 2,644.00 | -7.83% |
| NZX 50 Index | 11,775.88 | 449.40 | -3.68% |
| S&P 500 | 5,074.08 | 322.44 | -5.97% |
| S&P/ASX 200 | 7,343.30 | 324.50 | -4.23% |
| SSE Composite Index | 3,096.58 | 245.43 | -7.34% |